235 related articles for article (PubMed ID: 31281496)
1. Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma.
Mai J; Zhong ZY; Guo GF; Chen XX; Xiang YQ; Li X; Zhang HL; Chen YH; Xu XL; Wu RY; Yu Y; Li ZL; Peng XD; Huang Y; Zhou LH; Feng GK; Guo X; Deng R; Zhu XF
Theranostics; 2019; 9(12):3541-3554. PubMed ID: 31281496
[No Abstract] [Full Text] [Related]
2. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
3. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
4. Kinome inhibition reveals a role for polo-like kinase 1 in targeting post-transcriptional control in cancer.
Al-Qahtani QH; Moghrabi WN; Al-Yahya S; Al-Haj L; Al-Saif M; Mahmoud L; Al-Mohanna F; Al-Souhibani N; Alaiya A; Hitti E; Khabar KSA
Mol Oncol; 2021 Aug; 15(8):2120-2139. PubMed ID: 33411958
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.
Cheung AK; Ip JC; Lung HL; Wu JZ; Tsao SW; Lung ML
Mol Cancer Ther; 2013 Aug; 12(8):1393-401. PubMed ID: 23686835
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation by polo-like kinase 1 induces the tumor-suppressing activity of FADD.
Jang MS; Lee SJ; Kim CJ; Lee CW; Kim E
Oncogene; 2011 Jan; 30(4):471-81. PubMed ID: 20890306
[TBL] [Abstract][Full Text] [Related]
8. Loss of cytoplasmic KLF4 expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma.
Liu Z; Yang H; Luo W; Jiang Q; Mai C; Chen Y; Zhen Y; Yu X; Long X; Fang W
Histopathology; 2013 Sep; 63(3):362-70. PubMed ID: 23758499
[TBL] [Abstract][Full Text] [Related]
9. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
10. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
11. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer.
Shi W; Alajez NM; Bastianutto C; Hui AB; Mocanu JD; Ito E; Busson P; Lo KW; Ng R; Waldron J; O'Sullivan B; Liu FF
Int J Cancer; 2010 May; 126(9):2036-48. PubMed ID: 19739117
[TBL] [Abstract][Full Text] [Related]
12. Plk1-mediated phosphorylation of Topors regulates p53 stability.
Yang X; Li H; Zhou Z; Wang WH; Deng A; Andrisani O; Liu X
J Biol Chem; 2009 Jul; 284(28):18588-92. PubMed ID: 19473992
[TBL] [Abstract][Full Text] [Related]
13. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
[TBL] [Abstract][Full Text] [Related]
15. Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma.
Li X; Zhao Z; Yi S; Ma L; Li M; Liu M; Zhang Y; Liu G
J Transl Med; 2018 Jul; 16(1):183. PubMed ID: 29973197
[TBL] [Abstract][Full Text] [Related]
16. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.
Ji J; Yu Y; Li ZL; Chen MY; Deng R; Huang X; Wang GF; Zhang MX; Yang Q; Ravichandran S; Feng GK; Xu XL; Yang CL; Qiu MZ; Jiao L; Yang D; Zhu XF
Theranostics; 2018; 8(6):1494-1510. PubMed ID: 29556337
[No Abstract] [Full Text] [Related]
17. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
18. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
[TBL] [Abstract][Full Text] [Related]
19. PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
Tian L; Yao K; Liu K; Han B; Dong H; Zhao W; Jiang W; Qiu F; Qu L; Wu Z; Zhou B; Zhong M; Zhao J; Qiu X; Zhong L; Guo X; Shi T; Hong X; Lu S
Oncogene; 2020 Apr; 39(15):3145-3162. PubMed ID: 32060423
[TBL] [Abstract][Full Text] [Related]
20. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
